Teva wins FDA nod for sublingual film to treat opioid dependence

The FDA last week approved Teva Pharmaceuticals’ Cassipa buprenorphine and naloxone sublingual film as a maintenance treatment for opioid dependence.
There are a number of brand name and generic versions of buprenorphine and naloxone therapies that are delivered via a sublingual film. Teva’s product contains 16 milligrams buprenorphine and 4 milligrams of naloxone, bringing a new dosage strength to the market.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva wins FDA nod for sublingual film to treat opioid dependence appeared first on MassDevice.

Source: Mass Device - September 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Teva Pharmaceuticals Source Type: news